TVTX
HEALTHCARETravere Therapeutics Inc
AI Insight
What's Moving TVTX Today?
No stock-specific AI insight has been generated for TVTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.36$56.81
$55.95
Fundamentals
Market Cap$5.1B
P/E Ratio—
EPS$-0.50
Dividend Yield—
Dividend / Share—
ROE-69.4%
Profit Margin-4.0%
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding93.0M
TVTX News
24 articles- Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027Yahoo Finance·Jun 16, 2026
- TVTX Financials: Revenue Breakdown, Margins & Competitor ComparisonIntellectia AI·Jun 13, 2026
- Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?Yahoo Finance·Jun 13, 2026
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 11, 2026
- 3 Stocks That May Be Priced Below Their Estimated Value In June 2026Yahoo Finance·Jun 8, 2026
- Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 CongressYahoo Finance·Jun 4, 2026
- Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated ValueYahoo Finance·Jun 3, 2026
- 3 Stocks That May Be Priced Below Their Estimated Worth In June 2026Yahoo Finance·Jun 3, 2026
- TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% UpsideStocktwits·Jun 2, 2026
- Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney DiseasesYahoo Finance·Jun 2, 2026
- Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney DiseasesYahoo Finance·Jun 2, 2026
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA NephropathyYahoo Finance·May 27, 2026
- Discover 3 Stocks That May Be Trading Below Their Estimated ValueYahoo Finance·May 27, 2026
- Dow Jones Leader Amazon, AI Stock Quanta, Monster Beverage In Or Near Buy ZonesYahoo Finance·May 26, 2026
- 3 Stocks That May Be Undervalued By The Market In May 2026Yahoo Finance·May 21, 2026
- Fifth Third Bancorp And 2 Stocks Possibly Undervalued For ConsiderationYahoo Finance·May 21, 2026
- 3 Stocks Estimated To Be Trading Below Intrinsic Value By 11.4% To 38.4%Yahoo Finance·May 20, 2026
- Agilysys And Two Other Stocks Priced Below Estimated ValueYahoo Finance·May 20, 2026
- Discover 3 Stocks Including CoStar Group Estimated Below Intrinsic ValueYahoo Finance·May 19, 2026
- 3 Stocks That May Be Priced Below Their Estimated Value In May 2026Yahoo Finance·May 18, 2026
- Three Companies Priced Below Estimated Value In May 2026Yahoo Finance·May 18, 2026
- Travere Therapeutics Issues New Convertible Notes to Refinance DebtTipRanks·May 12, 2026
- Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains MattersThe Motley Fool·May 10, 2026
- Travere Therapeutics to Participate at Upcoming Investor Conferences - May 7, 2026BioSpace·May 8, 2026
All 24 articles loaded
Price Data
Open$54.43
Previous Close$55.11
Day High$56.01
Day Low$54.13
52 Week High$56.81
52 Week Low$14.36
52-Week Range
$14.36$56.81
$55.95
Fundamentals
Market Cap$5.1B
P/E Ratio—
EPS$-0.50
Dividend Yield—
Dividend / Share—
ROE-69.4%
Profit Margin-4.0%
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding93.0M
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—